Elanco, EnBiotix Establish Collaboration Exploring Engineered Phage Technology
June 16 2016 - 8:00AM
Business Wire
Collaboration to focus on alternatives to
existing antibiotics in the animal health market
Today Elanco Animal Health, a division of Eli Lilly and Company,
(NYSE: LLY) and EnBiotix, Inc., announced a collaboration to
explore the application of EnBiotix’s engineered phage technology
in specific animal health targets. If successful, this endeavor
could result in potential alternatives for traditional antibiotics
in animals.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160616005221/en/
“This collaboration furthers Elanco’s commitment to aggressively
seek and develop antibiotic alternatives as outlined in our
comprehensive antibiotic stewardship plan,” said Jeff Simmons,
President, Elanco Animal Health. “Innovative research will be key
to protecting both human and animal health while safeguarding
antibiotics for future generations.”
Phage therapy is an alternative and/or complementary approach to
traditional antibiotics for treating bacterial infections.
Bacteriophages are naturally-occurring viruses that only infect
bacteria and not humans. They self-replicate inside the bacteria,
harnessing bacterial machinery for DNA and protein synthesis and
ultimately killing the bacteria by lysis of the cell.
Under the terms of the agreement, Elanco and EnBiotix will
collaborate in animal health therapeutic areas to identify and
optimize drug candidates employing EnBiotix’s proprietary
engineered phage platform. Elanco will provide research funding and
will have an option to license and commercialize products arising
from the collaboration. All non-animal health uses for EnBiotix’s
technology platforms are excluded from the agreement.
Additional financial and other terms of the agreement were not
disclosed.
“Providing alternatives to current antibiotic treatments is a
key health objective and we are excited to apply EnBiotix’s
engineered phage technology platform in the animal health field
with Elanco,” said Jeffrey D. Wager MD, Chairman & CEO of
EnBiotix, Inc. “We have been impressed by Elanco’s comprehensive
antibiotic stewardship plan and they represent an ideal partner for
EnBiotix in this field.”
About ElancoElanco, a division of Eli Lilly and Company,
provides comprehensive products and knowledge services to improve
animal health and food-animal production in more than 70 countries
around the world. With a global presence of approximately 6,500
people and offices in more than 40 countries, Elanco anticipates,
serves and supports the diverse and evolving needs of its
customers--from veterinarians to food producers to all those
concerned with animal health--to help them address the challenges
of a diverse and changing world. Together with our customers, we
are committed to raising awareness about global food security, and
celebrating and supporting the human-animal bond. Additional
information about Elanco is available at www.elanco.com, or follow
us @Elanco.
About EnBiotixEnBiotix is an engineered antibiotics
company deploying novel systems and synthetic biology technologies
developed by Prof. James J. Collins, the Termeer Professor of
Medical Engineering & Science Professor, Department of
Biological Engineering, Massachusetts Institute of Technology.
These technologies enable the development of both novel antibiotics
and potentiators of existing antibiotics which have the potential
to transform their spectrum of activity and resistance profile.
With drug-resistant and drug-tolerant infections rapidly becoming a
global health crisis, EnBiotix’s robust product pipeline addresses
a wide range of acute and chronic infections to significantly
impact the lives of patients. For more information, please visit
www.enbiotix.com.
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about the collaboration between EnBiotix and Elanco, and
reflects Lilly, Elanco’s and EnBiotix’s current beliefs. However,
as with any animal health product, there are substantial risks and
uncertainties in the process of development and commercialization.
Among other things, there can be no guarantee that the research
collaboration will yield successful results, that either company
will achieve the anticipated benefits, or that the results will be
commercially successful. For further discussion of these and other
risks and uncertainties, see Lilly's most recent Form 10-K and Form
10-Q filings with the United States Securities and Exchange
Commission, respectively Except as required by law, Elanco and
EnBiotix undertakes no duty to update forward-looking statements to
reflect events after the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160616005221/en/
For Elanco Inquiries:Elanco Animal HealthKeri McGrath Happe,
+1-317-370-8394Communications
Managermcgrath_happeks@elanco.comorFor EnBiotix
Inquiries:MacDougall Biomedical CommunicationsKari Watson,
+1-781-235-3060kwatson@macbiocom.comorStefanie Tuck,
+1-781-235-3060stuck@macbiocom.com
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024